Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.

@article{Doubek2015OfatumumabAT,
  title={Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.},
  author={Michael Doubek and Yvona Brychtov{\'a} and Anna Panovsk{\'a} and Ludmila Sebejov{\'a} and Olga Stehl{\'i}kov{\'a} and Jana Chovancov{\'a} and Jitka Malcikova and Jana Smardov{\'a} and Karla Plevov{\'a} and Pavl{\'i}na Volfov{\'a} and Martin Trbu{\vs}ek and Marek Mr{\'a}z and Denisa Bake{\vs}ov{\'a} and Jakub Trizuljak and Marketa Hadrabova and Petra Obrtl{\'i}kov{\'a} and Josef Karban and Luk{\'a}{\vs} Smolej and Alexandra Oltov{\'a} and Eva Jel{\'i}nkov{\'a} and Sarka Pospisilova and Jiř{\'i} Mayer},
  journal={American journal of hematology},
  year={2015},
  volume={90 5},
  pages={417-21}
}
The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and toxicity of an ofatumumab-dexamethasone (O-Dex) combination in relapsed or refractory CLL. The trial was an… CONTINUE READING